Rheumatoid arthritis Musculoskeletal Diseases Other rheumatoid arthritis
Conditions
Interventions
After 3 months the patients who had not achieved low disease activity were randomised:
Treatment A: methotrexate with addition of sulphasalazine, 2000 mg/day, and hydroxychloroquine, 400 mg daily
Trea
Sponsors
Karolinska University Hospital (Sweden)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with early RA (disease duration less than 12 months) 2. Participated in the Swefot (SWEdish PHarmacOTherapy) study at Karolinska University Hospital at Huddinge 3. Patients started treatment with methotrexate 4. Active disease defined as a Disease Activity Score of 28 joints (DAS28) above 3.2 5. Aged between 18 and 80 years, either sex
Exclusion criteria
Exclusion criteria: 1. Prior DMARD therapy 2. Contraindication to any of the trial medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects of anti-TNF treatment on body composition and BMD beyond the anti-inflammatory effect. Assessed by dual X-ray absortiometry for total body, lumbar spine and femoral neck at the time of randomisation and after 12 and 24 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in serum levels of the adipokines adiponectin and leptin determined by radio immunoassay at randomisation and after 12 and 24 months. | — |
Countries
Sweden
Outcome results
None listed